Autopsy report · NCT06260748

A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Lack of feasibility”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 3
Sponsor: Leadiant Biosciences, Inc.
Sponsor type: Industry
Conditions: Cerebrotendinous Xanthomatoses
Interventions: Chenodeoxycholic acid; Chenodeoxycholic acid Placebo
Participants: 0
Sites: 1
Countries: Israel

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.